What is the 13F Pro Quality Score for AGIO?

13F Pro ranks AGIOS PHARMACEUTICALS, INC. (AGIO) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View AGIO's current score at https://13fpro.ai/research/AGIO (free sign-up required for the full ranking).

Which hedge funds own the most AGIO stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of AGIO include BlackRock,, FARALLON CAPITAL MANAGEMENT, STATE STREET. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/AGIO as soon as new 13F filings post.

Where does 13F Pro source AGIO data?

All AGIOS PHARMACEUTICALS, INC. fundamentals and ownership data come directly from SEC EDGAR. AGIOS PHARMACEUTICALS, INC. files with the SEC under CIK 1439222. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is AGIO in?

AGIOS PHARMACEUTICALS, INC. (AGIO) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is AGIO research updated on 13F Pro?

AGIO's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

AGIOS PHARMACEUTICALS, INC.(AGIO)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1439222 AGIO stock profile & AI dashboard →

13F Pro Quality Score

26.3/100

Rank #2,512 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

90.5/100

Profitability

3.0/100

Balance Sheet

7.2/100

Earnings Quality

30.0/100

Free Cash Flow

2.6/100

Institutional Flow

54.0/100

Revenue Scale

12.0/100

Dilution Risk

3.2/100

AGIO Stock Analysis & AI Quality Score

AI stock analysis and institutional research for AGIOS PHARMACEUTICALS, INC. (AGIO), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores AGIO at 26.3/100 on a 32-signal composite quality model, placing it at rank #2,512 of 2,879 stocks — the bottom half of the AI-ranked universe. AGIO scores in the top quartile across revenue growth (90.5). Areas of concern include free cash flow (2.6) and profitability (3.0), which score below median versus the broader universe. Shareholder dilution risk is elevated at 3.2/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), AGIOS PHARMACEUTICALS, INC. reports quarterly revenue of $20.7M, net income of $-99.1M, free cash flow of $-119.7M. Top institutional holders of AGIO by reported 13-F value include BlackRock,, FARALLON CAPITAL MANAGEMENT, STATE STREET, based on the most recent SEC filings. AGIO trades on the Nasdaq exchange and files with the SEC under CIK 1439222. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate AGIO daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for AGIOS PHARMACEUTICALS, INC. directly from SEC EDGAR. AGIOS PHARMACEUTICALS, INC.'s 13F Pro composite quality score has ranged between 24 and 65 since 2024, currently 26.3 — a declining long-term trajectory across 15 quarterly and live scoring snapshots.

✦

Fun facts about AGIOS PHARMACEUTICALS, INC.

Quirks, history, and lore behind AGIO — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. biopharmaceutical company · listed on Nasdaq · headquartered in Cambridge, Massachusetts · focused on cancer and rare diseases.
2
The Numbers
A small-cap biopharma with revenues in the low hundreds of millions — modest by pharma standards, but built on a handful of highly specialized drugs.
3
The History
Founded in 2008, it spun out of academic research and built its pipeline around cellular metabolism — the study of how cells make and use energy, particularly in cancer.
4
The Secret
Its drugs target mutant IDH enzymes — molecular culprits found in certain leukemias and other cancers — a mechanism most pharma giants overlooked for years.
5
The Lore
It sold its oncology business to Servier in a landmark deal, then reinvented itself around rare blood disorders like pyruvate kinase deficiency — a disease most doctors had never treated.
6
The Giveaway
Its approved drug mitapivat targets pyruvate kinase deficiency, and its ticker is a Greek word meaning something holy — fitting for a company hunting cures in the chemistry of life itself.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$20.7M

Net Income

Q1 2026

$-99.1M

Free Cash Flow

Q1 2026

$-119.7M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+48.0% YoY

$54.0MFY 2025

FY22 $14.2MFY23 $26.8MFY24 $36.5MFY25 $54.0M

Net Income

-161.2% YoY

$-412.8MFY 2025

FY22 $-231.8MFY23 $-352.1MFY24 $674.0MFY25 $-412.8M

Operating Income

-10.9% YoY

$-472.1MFY 2025

FY22 $-389.0MFY23 $-391.5MFY24 $-425.7MFY25 $-472.1M

EPS (Diluted)

-161.2% YoY

$-7.12FY 2025

FY22 $-4.23FY23 $-6.33FY24 $11.64FY25 $-7.12

Total Assets

-22.0% YoY

$1.30BFY 2025

FY22 $1.24BFY23 $937.1MFY24 $1.66BFY25 $1.30B

Op. Cash Flow

+4.3% YoY

$-373.0MFY 2025

FY22 $-309.5MFY23 $-296.1MFY24 $-389.8MFY25 $-373.0M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2020	FY 2019
Revenue	$54.0M +48.0%	$36.5M +36.1%	$26.8M +88.4%	$14.2M	$0.00 -100.0%	$117.9M
Net Income	$-412.8M -161.2%	$674.0M +291.4%	$-352.1M -51.9%	$-231.8M +29.2%	$-327.4M +20.4%	$-411.5M
Operating Income	$-472.1M -10.9%	$-425.7M -8.7%	$-391.5M -0.6%	$-389.0M -15.8%	$-335.9M -6.2%	$-316.3M
EPS (Diluted)	$-7.12 -161.2%	$11.64 +283.9%	$-6.33 -49.6%	$-4.23 +10.8%	$-4.74 +30.9%	$-6.86
Total Assets	$1.30B -22.0%	$1.66B +77.5%	$937.1M -24.3%	$1.24B +45.2%	$853.0M -4.2%	$890.7M
Operating Cash Flow	$-373.0M +4.3%	$-389.8M -31.7%	$-296.1M +4.3%	$-309.5M -6.4%	$-290.8M +21.5%	$-370.6M

AI Insight: AGIO Financial Trends

Revenue doubled from $9M to $21M over eight quarters, but equity erosion accelerating as cumulative operating losses consume the Q3 2024 windfall.

• Revenue grew from $9M in Q2 2024 to $21M in Q1 2026, a ~133% increase over eight quarters.

• Equity has declined every quarter since the Q3 2024 peak of $1,627M, falling to $1,109M in Q1 2026 — a $518M drawdown.

• Operating losses remain wide, ranging from $-103M to $-127M over the past five quarters with no clear narrowing trend.

• Operating cash outflow in Q1 2026 was $-119M, the second-largest in the dataset, despite rising revenue.

⚠ Equity runway: at current burn rate (~$90M/quarter), the $1,109M equity cushion supports roughly 12 quarters without new capital.

⚠ Revenue inflection is real but operating leverage has not materialized; watch whether Q2 2026 losses begin to narrow meaningfully.

⚠ No debt reported across all eight quarters; any introduction of leverage would signal a balance-sheet regime change worth monitoring.

AI Insight: AGIO Ratio Trends

AGIOS remains deeply loss-making with no margin data available, but ROIC has partially recovered from a Q2 2024 trough of -64.1% to -39.7% in Q1 2026.

• ROIC improved significantly from -64.1% in Q2 2024 to -29.1% in Q1 2025, suggesting reduced capital destruction rate mid-cycle.

• ROIC deteriorated from -29.1% in Q1 2025 to -39.7% in Q1 2026, reversing the earlier improvement over four consecutive quarters.

• OpMargin, NPM, and D/E are unavailable across all periods, limiting visibility into operating efficiency and leverage profile.

⚠ ROIC has worsened four straight quarters from -29.1% in Q1 2025 to -39.7% in Q1 2026 — sustained capital destruction acceleration warrants close monitoring.

⚠ TTM ROIC of -42.9% is worse than any single quarter shown since Q2 2024, flagging potential one-off drag or compounding losses.

Get alerted when AGIO's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for AGIOS PHARMACEUTICALS, INC. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of AGIO

BlackRock, Inc.
$194.7M5,754,957 sh
FARALLON CAPITAL MANAGEMENT LLC
$192.3M5,684,000 sh
STATE STREET CORP
$113.7M3,364,879 sh
ARMISTICE CAPITAL, LLC
$108.3M3,200,000 sh
ARMISTICE CAPITAL, LLC
$91.9M2,716,000 sh
D. E. Shaw & Co., Inc.
$90.7M2,681,169 sh
VANGUARD CAPITAL MANAGEMENT LLC
$89.1M2,632,316 sh
Lynx1 Capital Management LP
$88.3M2,611,568 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$88.3M2,611,035 sh
Erste Asset Management GmbH
$80.1M2,704,900 sh

Fund	Value	Shares
BlackRock, Inc.	$194.7M	5,754,957
FARALLON CAPITAL MANAGEMENT LLC	$192.3M	5,684,000
STATE STREET CORP	$113.7M	3,364,879
ARMISTICE CAPITAL, LLC	$108.3M	3,200,000
ARMISTICE CAPITAL, LLC	$91.9M	2,716,000
D. E. Shaw & Co., Inc.	$90.7M	2,681,169
VANGUARD CAPITAL MANAGEMENT LLC	$89.1M	2,632,316
Lynx1 Capital Management LP	$88.3M	2,611,568
VANGUARD PORTFOLIO MANAGEMENT LLC	$88.3M	2,611,035
Erste Asset Management GmbH	$80.1M	2,704,900

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put AGIO on your watchlist

Track score changes the day AGIOS PHARMACEUTICALS, INC. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is AGIO a good stock to buy?

13F Pro's AI-powered analysis of AGIOS PHARMACEUTICALS, INC. (AGIO) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for AGIO are available on the AGIO stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own AGIO?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling AGIO. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of AGIOS PHARMACEUTICALS, INC.'s investment landscape.